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Abstract.
Background: Urate and homocysteine are potential biomarkers for disease progression in Parkinson’s disease (PD). Baseline
serum urate concentration has been shown to predict motor but not cognitive decline. The relationship between serum
homocysteine concentration and cognitive and motor impairment is unknown.
Objectives: The aim of this study was to examine the association between baseline serum urate and homocysteine, and
prospective measures of disease progression and cognition over 54 months in early PD.
Methods: 154 newly diagnosed PD participants and 99 age-matched controls completed a schedule of assessments at baseline,
18, 36 and 54 months. The Movement Disorders Society Unified Parkinson’s Disease Scale Part III (MDS-UPDRS III) was
used to assess motor severity. The Montreal Cognitive Assessment (MoCA) was used to assess global cognition. Serum
samples drawn at baseline were analysed for urate, homocysteine, red cell folate and vitamin B12 concentrations.
Results: Baseline urate was 331.4 ± 83.8 and 302.7 ± 78.0mol/L for control and PD participants, respectively (p = 0.015).
Baseline homocysteine was 9.6 ± 3.3 and 11.1 ± 3.8mol/L for controls and PD participants, respectively (p < 0.01). Linear
mixed effects modelling showed that lower baseline urate (= 0.02, p < 0.001) and higher homocysteine (= 0.29, p < 0.05)
predicted decline in motor function. Only higher homocysteine concentrations at baseline, however, predicted declining
MoCA scores over 54 months (= 0.11, p < 0.01).
Conclusions: Lower serum urate concentration is associated with worsening motor function; while higher homocysteine
concentration is associated with change in motor function and cognitive decline. Therefore, urate and homocysteine may be
suitable biomarkers for predicting motor and cognitive decline in early PD.
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INTRODUCTION
Parkinson’s disease (PD) is a progressive neurode-
generative disorder encompassing motor, cognitive
and behavioural and autonomic features. There is
growing evidence that oxidative stress is involved
in the pathophysiology, disease progression and
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development of cognitive impairment in PD.
Dopaminergic neurons in the basal ganglia are par-
ticularly susceptible to oxidative stress [1] and the
post-mortem brains of PD subjects have higher con-
centrations of the products of oxidative stress than
controls [2].
Both urate and homocysteine may have a role in
regulating oxidative stress in PD. Urate is a prod-
uct of purine breakdown, which accounts for 60% of
serum antioxidant capacity [3]. Prospective studies
have shown that low serum urate in middle age is
associated with an increased risk of developing PD
over the subsequent 15–20 years, with participants in
the lowest quartile 2.3–2.5 times as likely to develop
the condition than those in the highest quartile [4,
5]. Furthermore, amongst patients with newly diag-
nosed PD who had not yet started treatment, those
with the highest quintile of urate were half as likely
to require treatment than those in the lowest quin-
tile over the following two years [6]. Low plasma
urate in PD patients has also been associated with
poorer performance in neuropsychological tests sen-
sitive to attention, executive function and visuospatial
function [7], suggesting it may be associated with
cognitive impairment.
The association between hyperhomocysteinaemia
and risk of dementia in community dwelling older
adults has been previously reported [8], raising
the possibility that it may also have a role in the
development of PD dementia (PDD). In established
PD, cross-sectional studies have reported that ele-
vated plasma homocysteine levels are associated with
dementia [9].
The aim of this study was to examine the associa-
tion between baseline serum urate and homocysteine
and measures of disease progression in early PD using
participants in an incident cohort study with prospec-
tive follow up. We hypothesised that PD patients with
low urate and/or high homocysteine at baseline would
display a more rapid decline in motor and cognitive
function over the 54 month follow up.
PARTICIPANTS AND METHODS
Subjects
Participants were recruited prospectively as part
of the Incidence of Cognitive Impairment in Cohorts
with Longitudinal Evaluation in Parkinson’s disease
(ICICLE-PD) study [10] Inclusion criteria com-
prised a diagnosis of idiopathic PD according to UK
Brain Bank Criteria [11] in the North East of Eng-
land between 1 June 2009 and 31 December 2011.
Exclusion criteria were: significant cognitive impair-
ment at presentation (Mini Mental State Examination
(MMSE) score <24) or a diagnosis of dementia,
parkinsonism due to another cause, insufficient work-
ing knowledge of English, major psychiatric illness
or treatment with COMT inhibitors.
To generate normative values, age-matched
healthy control subjects were recruited from local
advertising and community sources. Carers and
spouses of patients with PD were not approached
to act as controls to limit bias. Exclusion criteria
for controls were: significant cognitive impairment at
presentation (MMSE <24) or diagnosis of dementia,
major psychiatric illness or movement disorder.
The study was approved by Newcastle and North
Tyneside Research Ethics Committee. All partic-
ipants provided written informed consent at each
review.
Assessments
Demographic information including age, sex, and
education were collected. All subjects underwent a
medical assessment by a movement disorders special-
ist; we sought details of disease duration, co-morbid
diseases, medication use, smoking history and alco-
hol consumption. Patients were evaluated in the “on”
motor state. Motor severity was rated using the Move-
ment Disorders Society Unified Parkinson’s Disease
Rating Scale (MDS-UPDRS) Part III [12] and Hoehn
and Yahr scale [13]. MDS-UPDRS scores range from
0–132, with higher scores indicating more severe
motor symptoms. Levodopa equivalent daily dose
(LEDD) was calculated for all dopaminergic med-
ications [14]. Participants completed the National
Adult Reading Test (NART) [15] as a measure of
pre-morbid IQ and the Geriatric Depression Scale
(GDS) [16] was used to measure depressive symp-
toms. Global cognitive function was assessed with the
Mini-Mental State Examination (MMSE) [17] and
Montreal Cognitive Assessment (MoCA). Both tests
have a maximum score of 30 with a score of <26 sug-
gesting cognitive impairment. The MoCA has been
validated in patients with PD [18]. Assessments were
repeated at 18-month intervals.
Laboratory analyses
A single baseline non-fasting blood sample was
obtained for measurements of total serum urate,
plasma homocysteine, vitamin B12 and red cell folate
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concentrations. A serum separate tube (SST) was col-
lected for urate analysis, which was later determined
using an enzymatic (Uricase) method on the Roche
Modular P. Homocysteine samples were collected
into citrate plasma tubes and put on ice immediately.
Total plasma homocysteine was measured using an
automated latex immunoassay (Hemosil, Homocys-
teine, Instrumentation Laboratory) on the IL-TOP
Coagulation analyser. Vitamin B12 and red cell folate
samples were collected into EDTA plasma tubes;
levels were determined using a chemiluminescent
microparticle assay (Architect, Abbott).
Statistical analyses
Data were analysed using SPSS (Version 21,
Armonk, NY: IBM Corp). Data were examined
for normality by visual inspection of histograms
and Kolmogorov-Smirnov testing. Comparison of
means between PD and control subjects at baseline
were performed using independent t-tests or Mann-
Whitney U tests as appropriate. For comparisons of
repeated measures between baseline and 54 months,
repeated measures ANOVA or Friedman tests were
used as appropriate. Chi-squared testing was used
to assess binary outcome variables. The signifi-
cance level for all statistical tests was set at = 0.05
(two-tailed).
R [19] and lme4 [20] were used to perform lin-
ear mixed effects analysis. A random intercept model
was used to determine baseline predictors of change
in motor severity and global cognition from base-
line to 54 months in PD subjects. The intercept
varied at the participant and time level, accounting
for by-subject and by-time variability. A reduced
model was produced by excluding non-significant
predictors to which baseline serum urate or baseline
plasma homocysteine were then added, in addition
to baseline folate and vitamin B12 and their inter-
actions with time as covariates. Baseline age, sex,
LEDD, time, age × time and LEDD × time were
entered into the model as fixed factors predicting
change in PD motor severity. Baseline age, sex,
years of education, LEDD, MDS-UPDRS III, GDS-
15 and time were added as fixed factors predicting
change in MoCA score, as well as interactions of
time with baseline age (age × time), motor severity
(MDS-UPDRS III × time), LEDD (LEDD × time)
and GDS-15 (GDS-15 × time). LEDD was controlled
for in all models that included total plasma homo-
cysteine (tHyc). To account for confounders that
may mediate the relationship between urate and/or
tHyc, we repeated the above analysis adjusting for
the presence of baseline smoking status, type II dia-
betes, hypertension, ischemic heart disease, previous
stoke or transient ischemic attack (TIA), hyperc-
holesterolemia and gout. Visual inspection of residual
plots did not reveal any obvious deviations from
homoscedasticity or normality. Fit of the models was
assessed by likelihood ratio tests.
RESULTS
After exclusions, at baseline 154 patients with
PD and 99 healthy control subjects completed
assessments (Fig. 1). The demographic and clini-
cal characteristics of the PD participants and control
subjects at baseline were compared (Table 1). Mean
time from PD diagnosis was 6.3 ± 6.1 months. There
were no significant differences between PD partic-
ipants and controls with regard to age, sex, years
of education or smoking status (p > 0.05 for all).
Previous stroke or TIAs were more common in
those with PD than controls (10 vs. 0 patients,
p < 0.01), but there were no differences in rates of
ischaemic heart disease, hypertension, hypercholes-
terolaemia, gout or type 2 diabetes. PD participants
scored significantly poorer on both the MoCA and
MMSE as measures of global cognition (p < 0.01 for
both). At 54 month evaluation n = 91 PD participants
(58%) and 69 control participants (68%) returned
(Fig. 1). In total, 18 PD participants declined further
follow up, 35 were lost to follow up and 10 were
deceased. There were no significant differences in
either PD or control subjects who completed all
assessments compared those who did not, in terms of
baseline age, NART scores, GDS-15, LEDD, MMSE,
urate or homocysteine concentrations (p > 0.05
for all). At baseline completers had completed
more years of education (13.3 ± 3.8 vs. 12.0 ± 3.7,
Z = –2.3, p = 0.024), a lower MDS-UPDRS III score
(24.2 ± 10.5 vs. 30.8 ± 13.2, Z = –3.1, p = 0.002)
and higher MoCA score (25.8 ± 3.3 vs. 24.3 ± 3.9,
Z = –2.4, p = 0.018).
CHANGES IN SERUM URATE AND
HOMOCYSTEINE
Total plasma urate concentration was signifi-
cantly lower in those with PD than in controls
at baseline (302.7 ± 77.9 vs. 331.4 ± 77.9mol/L,
respectively, p < 0.01), 18 months (301.9 ± 77.0
vs. 339.4 ± 90.7mol/L, respectively, p < 0.01) and
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Fig. 1. Consort diagram of Parkinson’s disease and control participants.
36 months (305.0 ± 76.4 vs. 331. ± 79.7mol/L,
respectively, p < 0.05). Within groups, there was no
significant change over time in urate concentrations
for either PD or control participants using repeated
measures analysis (p > 0.05). Four participants with
PD and one control were taking allopurinol at base-
line. For both PD and control participants, urate
concentrations were significantly higher in males
compared to females at each time point (p < 0.001
for all, Supplementary Table 1).
In comparison, the total plasma homocysteine
concentration was significantly higher in those
with PD than in controls at baseline (11.1 ± 3.8
vs. 9.6 ± 3.3mol/L, respectively, p < 0.01), 18
months (12.3 ± 3.8 vs. 11.1 ± 3.7mol/L, respec-
tively, p < 0.05) and 36 months 13.9 ± 4.9 vs.
12.3 ± 4.2mol/L, respectively, p < 0.05). However,
repeated measures analysis showed plasma homo-
cysteine significantly increased in both groups over
36 months (p < 0.01 for both). At baseline, females
control participants had significantly lower plasma
homocysteine concentrations compared to males
(8.8 ± 2.9 vs. 10.2 ± 3.5, respectively, p < 0.05) but
at no other time point. In PD participants, there were
no significant differences in males and females at
baseline, 18 and 36 months, but females had sig-
nificantly lower plasma homocysteine concentrations
compared to males at 54 months (11.4 ± 2.3 vs.
14.6 ± 5.0mol/L, respectively, p < 0.05).
At baseline, 73% of PD participants were lev-
odopa naı¨ve. Comparison of mean tests found no
significant differences between levodopa treated and
levodopa naı¨ve participants for serum urate con-
centrations (307.5 ± 71.2 vs. 301.3 ± 73.9mol/L,
respectively, p > 0.05) or serum homocysteine
concentrations (11.8 ± 3.4 vs. 10.9 ± 4.0mol/L,
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Table 1
Baseline demographic and clinical characteristics of the study participants
Control PD t/z p
Mean SD Mean SD
Age (years) 67.9 8.2 66.4 10.4 1.2 0.214
Education (years) 13.1 3.4 12.8 3.8 –1.1 0.251
NART 115.9 8.7 114.7 10.7 –0.3 0.770
PD duration (months) – – 6.4 6.0 – –
MDS-UPDRS III – – 26.9 12.1 – –
Hoehn and Yahr – – 2.0 0.7 – –
LEDD (mg/d) – – 178.0 148.2 – –
GDS-15 1.0 1.5 2.8 2.5 –6.87 <0.001
MoCA 27.0 2.5 25.2 3.7 –3.7 <0.001
MMSE 29.0 1.2 28.6 1.3 –2.7 0.006
BMI 27.7 3.9 27.2 4.8 0.8 0.411
Urate (mol/L) 331.4 83.8 302.7 77.9 –2.4 0.015
Homocysteine (mol/L) 9.6 3.3 11.1 3.8 –3.8 <0.001
Vitamin B12 (pg/mL) 472.6 171.1 391.5 170.0 –4.1 <0.001
Red cell folate (ng/ml) 324.4 162.0 277.2 148.5 –3.0 0.003
n % n % χ2 p
Sex (male) 54 54.5 100 64.9 2.7 0.098
Smoker 7 7.1 9 5.8 0.4 0.725
Hypertension 35 35.4 48 31.2 0.5 0.989
Type 2 diabetes mellitus 5 5.1 12 7.8 0.7 0.395
Ischaemic heart disease 9 9.1 18 11.7 0.4 0.514
Previous stroke or transient ischaemic attack 0 0.0 10 6.5 6.7 0.010
Hypercholesterolaemia 17 17.2 22 14.3 0.4 0.535
Gout 3 3.0 5 3.2 0 0.924
PD, Parkinson’s disease; SD, Standard deviation; NART, National Adult Reading Test; MDS UPDRS III, Movement Disorders Society
Unified Parkinson’s Disease Rating Scale Part III; LEDD, Levodopa equivalent daily dose; GDS-15, Geriatric Depression Scale; MoCA,
Montreal Cognitive Assessment; MMSE, Mini Mental State Examination. Significant results are highlighted in bold.
respectively, p > 0.05). However, urate concentration
was significantly lower in levodopa naı¨ve PD par-
ticipants compared to healthy controls (301.3 ± 73.9
vs. 331.4 ± 83.8mol/L, respectively, p < 0.05),
while homocysteine concentration was significantly
higher (10.9 ± 4.0 vs. 9.6 ± 3.3mol/L, respectively
<0.05).
Baseline predictors of motor severity and
cognition over 54 months
Multivariate modelling was used to determine the
effects of baseline homocysteine and urate on change
in motor severity and change in cognition over 54
months, respectively. Linear mixed effects modelling
was used to predict motor severity (MDS-UPDRS
III). After excluding non-significant predictors, age
(= –4.0, p < 0.05), sex (= 0.2, p < 0.01) and time
(= 5.2, p < 0.01) were controlled for in the basic
model.
The interaction of baseline urate with time was
a significant predictor of change in MDS-UPDRS
III score (p < 0.001), after controlling for B12 and
folate concentrations, indicating that low urate levels
at diagnosis were associated with declining motor
severity (Table 2). Adding urate, urate × time and
covariates significantly improved the fit of the model
(χ2 = 437.1, p < 0.001). The basic model plus tHyc
and tHyc × time, controlling for LEDD, B12 and
folate, was also a significantly stronger model than
the basic model (χ2 = 405.1 p < 0.001). However,
only tHyc × time was significant predictor. There was
no significant difference in fit between these two
models (p > 0.05). Including both urate × time and
tHyc × time, controlling for LEDD, B12 and folate,
showed that both low urate and high tHyc predicted
declining motor severity (Table 2). However, the
model suggested that when taking into account both
urate and tHyc, baseline urate was the stronger pre-
dictor of change in motor severity (t = 3.5, p < 0.001
vs. t = 2.4, p < 0.05, respectively). The basic model
plus urate and homocysteine had stronger predic-
tive power than urate alone (χ2 = 77.2, p < 0.001) or
homocysteine alone (χ2 = 109.3, p < 0.001).
Baseline predictors of MoCA score over 54 months
were age (= –0.16, p < 0.001), MDS-UPDRS III
score (= –0.05, p < 0.01), time (= 1.14, p < 0.01)
and MDS-UPDRS × time (= –0.03, p < 0.001) and
were included in the basic model. Due to sex
differences in baseline urate concentration, sex
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Table 2
Baseline predictors of motor severity over 54 months using linear
mixed effects modelling
 SE t p-value
Basic modela + urate
Urate –0.01 0.0 –0.8 0.422
Urate × Time 0.02 0.0 4.5 <0.001
Basic modelb + homocysteine
tHyc 0.48 0.3 1.7 0.094
tHyc × Time 0.44 0.1 3.8 <0.001
Basic modelb + urate + homocysteine
Urate –0.02 0.0 –1.0 0.313
tHyc 0.57 0.3 2.0 0.052
Urate × Time 0.02 0.0 3.5 <0.001
tHyc × Time 0.29 0.1 2.4 0.016
Motor severity determined by MDS-UPDRS III. Significant
predictors highlighted in bold. aCovariates included in model:
age, sex, folate, B12, time, folate × time and B12 × time.
bCovariates included in model: age, sex, LEDD, folate, B12, time,
LEDD × time, folate × time and B12 × time. MDS-UPDRS III,
Movement Disorder Society Unified Parkinson’s Disease Rating
Scale Part III; LEDD, Levodopa equivalent daily dose; tHyc, serum
homocysteine.
Table 3
Baseline predictors of global cognition over 54 months using linear
mixed effects modelling
 SE t p-value
Basic modela + urate
Urate 0.00 0.00 –1.03 0.305
Urate × Time 0.00 0.00 1.38 0.170
Basic modelb + homocysteine
tHyc –0.05 0.09 –0.53 0.598
tHyc × Time 0.12 0.04 2.89 0.004
Basic modelb + urate + homocysteine
Urate –0.01 0.00 –1.13 0.261
tHyc –0.04 0.09 –0.42 0.678
Urate × Time 0.00 0.00 0.94 0.346
tHyc × Time 0.11 0.04 2.70 0.007
Global cognition determined by MoCA. Significant predictors
highlighted in bold. aCovariates included in model: sex, age,
MDS-UPDRS III, folate, B12, time, folate × time and B12 × time.
bCovariates included in model: sex, age, MDS-UPDRS III, LEDD,
folate, B12, time, LEDD × time, folate × time and B12 × time.
MoCA, Montreal Cognitive Assessment; MDS-UPDRS III, Move-
ment Disorder Society Unified Parkinson’s Disease Rating Scale
Part III; LEDD, Levodopa equivalent daily dose; tHyc, serum
homocysteine.
was controlled for in the basic model. Urate and
urate × time were not significant predictors of change
in MoCA score (p > 0.05, Table 3). When tHyc and
tHyc × time were added to the basic model, con-
trolling for LEDD, B12 and folate, tHyc × time
was a significant predictor of MoCA score over
time (Table 3) and the model significantly improved
(χ2 = 230.0, p < 0.001).
DISCUSSION
We found that participants with early PD had lower
serum urate and higher serum homocysteine than age-
matched controls. Mixed effect modelling revealed
that lower urate and higher homocysteine at baseline
predicted worse motor scores over 54 months, while
only high baseline homocysteine predicted declining
MoCA scores.
In keeping with previous studies, our cohort of PD
participants had significantly lower serum urate con-
centrations than controls [6, 21]. These studies also
found a correlation between lower baseline urate and
worsening motor function; however, our study design
differed in a number of ways. While we recruited
patients with mean disease duration of six months,
the other studies recruited PD patients, who did not
require levodopa, with disease duration of up to
five years. Our end-point was a motor progression
over 54 months using the MDS-UPDRS III, whilst
the end-point in others studies was the initiation of
dopaminergic therapy over the two-year follow up
period.
Low serum urate concentration predicted worsen-
ing motor symptoms over 54 months. The protective
effect of urate is thought to relate to its abil-
ity to act as a physiological buffer to oxidative
stress [3]. Evidence from human post-mortem stud-
ies suggests dopaminergic neurons in the substantia
nigra of PD patients are subject to higher levels of
oxidative stress than controls [1]. Rodents have an
enzyme, urate oxidase, which breaks down urate;
urate oxidase is not present in humans. Transgenic
urate oxidase knockout mice, who consequently have
higher levels of circulating urate, were shown to
lose fewer nigral dopamine neurons in response to
an intrastriatal injection of the dopaminergic toxin
6-hydroxydopamine, than wild-type mice [22]. Our
findings provide further evidence of the effects of
urate on progression of PD even in early disease,
and therefore, its role as a possible therapeutic tar-
get. A recent placebo controlled trial has shown that
inosine administration increases urate concentration
and oxidative capacity in patients with early PD [23].
The increased oxidative capacity, as measured by
the ferric reducing property of plasma assay, was
associated with reduced change in the UPDRS III
over six months. This result provides evidence of the
therapeutic potential of inosine to increase urate con-
centration, although further longitudinal evaluation
is needed.
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Homocysteine was significantly higher in newly
diagnosed PD compared to controls. This is consis-
tent with a previous study in established PD [24].
Homocysteine was also associated with increasing
motor severity and cognitive impairment. This is
consistent with the findings of O’Suilleabhain and
colleagues [25] who reported that in patients with
established PD, those with hyperhomocysteinaemia
performed worse on a range of neuropsychomet-
ric tests despite comparable motor severity. 20% of
patients with hyperhomocysteinaemia in the original
cohort were not included in the longitudinal anal-
yses, however, because of excess mortality in this
group.
Increasing evidence suggests that the pathology
of PD dementia includes a synergistic effect of
-synuclein and amyloid pathologies. Post-mortem
studies of PD subjects have shown that there is a
significant correlation between the extent of amyloid
deposition and Lewy body pathology [26]. Interest-
ingly, in the EXPRESS trial, patients with PDD and
hyperhomocysteinaemia showed a more favourable
response to rivastigmine therapy on measures of
cognition, functioning and neuropsychiatric symp-
tomatology than those in the normal range [27],
suggesting that stratifying patients by homocys-
teine level may be useful for predicting response to
treatment.
While raised plasma homocysteine is an estab-
lished risk factor for cardiovascular disease [28],
its role in diseases of the nervous system if still
under investigation. Homocysteine acts as an N-
Nitrosodimethylamine (NMDA) receptor agonist on
cultured cortical neurons, leading to neuronal death
[29]. In the basal ganglia, five days of homocysteine
administration into the lateral ventricle of rats led to
reduced levels of striatal dopamine and metabolites,
and a decreased number of spontaneous movements
[30]. One possible mechanism for this is increased
oxidative stress; Bhattacharjee et al. has shown that
60 days of systemic administration of homocysteine
increases striatal levels of superoxide dismutase [31].
Strengths of the current study include the recruit-
ment of a cohort of patients with early PD, many of
whom had low levels of motor impairment and not
yet established on levodopa therapy. The inclusion of
a matched control group was important to control for
the effects of normal ageing. The study also used a
range of validated assessments, which were repeated
every 18 months.
Potential limitations of this study include the non-
inclusion of patients who declined to be part of the
ICICLE-PD study. The participants who declined to
take part in the study may have been those with more
rapid motor and cognitive decline and therefore of
particular interest. Our homocysteine and urate levels
were based on a single non-fasting measurement and
fluctuations in homocysteine levels over time may
be important. A single homocysteine measurement
may underestimate the risk of the outcome of inter-
est due to regression dilution bias [32]. Although
this study is large in comparison to other studies
in PD, our sample size is small in comparison to
studies of non-PD populations [8, 33]. Nevertheless,
we were still able to demonstrate that impaired cog-
nition was associated with increased homocysteine
levels.
Only a small proportion of PD participants were
drug naive (12.3%) at baseline and our cohort con-
tained a mixture of participants on and off levodopa
therapy. This could have implications for our results
as previous studies have shown that levodopa acutely
increases homocysteine concentration [34]. How-
ever, we controlled for LEDD as part of our analysis
to minimise the effects. As with many longitudinal
studies, missing data was an issue; 58% of PD partic-
ipants and 68% of controls completed assessments at
each time point. This has implications for data inter-
pretation as participants who did not return for further
evaluation may have been those with a more rapid
decline in PD and cognition, and would therefore
have been of particular interest to this study. How-
ever, we used mixed effects modelling as part of our
analysis. This form of multilevel modelling has the
ability to handle missing data points, and so the omis-
sion of individual variables at one time point does not
result in all of the data for that subject being excluded
from analysis.
In conclusion, we have shown that in a longitudinal
study of PD subjects, urate and homocysteine predict
motor progression over 54 months, while homocys-
teine predicted cognitive decline. These findings lend
support to the hypothesis that oxidative stress may
play a role in the pathophysiology of PD and that
motor and cognitive aspects of the disease may have
overlapping but separate mechanisms. This hypoth-
esis would require further investigation in order to
develop robust neuroprotective strategies to alter the
disease trajectory. In addition to potential disease
modification, our findings suggest that determining
urate and homocysteine concentration at the out-
set may have a role in predicting patients with PD
at greater risk of decline in motor and cognitive
function.
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